WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018041838) ADENOVIRUS ARMED WITH BISPECIFIC T CELL ENGAGER (BITE)
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/041838    International Application No.:    PCT/EP2017/071674
Publication Date: 08.03.2018 International Filing Date: 29.08.2017
IPC:
A61K 39/395 (2006.01), A61K 35/761 (2015.01), C07K 16/28 (2006.01), C07K 16/30 (2006.01), C07K 16/40 (2006.01), C12N 15/861 (2006.01)
Applicants: PSIOXUS THERAPEUTICS LIMITED [GB/GB]; PsiOxus House 4-10 The Quadrant Abingdon, Oxfordshire OX14 3YS (GB)
Inventors: CHAMPION, Brian, Robert; (GB).
BROWN, Alice, Claire, Noel; (GB).
FREEDMAN, Joshua, David; (GB).
FISHER, Kerry, David; (GB).
SEYMOUR, Leonard, William; (GB)
Agent: STERLING IP LTD; Orion House Bessemer Road Welwyn Garden City United Kingdom AL7 1HH (GB)
Priority Data:
1614607.8 29.08.2016 GB
1700663.6 13.01.2017 GB
1706219.1 19.04.2017 GB
1713765.4 28.08.2017 GB
Title (EN) ADENOVIRUS ARMED WITH BISPECIFIC T CELL ENGAGER (BITE)
(FR) ADÉNOVIRUS ÉQUIPÉ D'UN ACTIVATEUR DE LYMPHOCYTES T BISPÉCIFIQUE (BITE)
Abstract: front page image
(EN)A modified adenovirus, in particular Enadenotucirev (EnAd), armed with a bispecific T cell engager (BiTE) comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus.
(FR)L'invention concerne un adénovirus modifié, en particulier l'énadénotucirev (EnAd), équipé d'un activateur de lymphocytes T bispécifique (BiTE) comprenant au moins deux domaines de liaison, au moins l'un des domaines étant spécifique pour un antigène de surface présent sur un lymphocyte T d'intérêt. L'invention concerne également une composition, telle qu'une formulation pharmaceutique comprenant le virus, l'utilisation du virus et des formulations de virus à but thérapeutique, par exemple pour le traitement du cancer. L'invention concerne également des procédés de préparation du virus.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)